Nintedanib in patients with idiopathic pulmonary fibrosis: Combined evidence from the TOMORROW and INPULSIS® trials-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Nintedanib in patients with idiopathic pulmonary fibrosis: Combined evidence from the TOMORROW and INPULSIS® trials

Published:2016-04 Issue: Volume:113 Page:74-79
ISSN:0954-6111
Container-title:Respiratory Medicine
language:en
Short-container-title:Respiratory Medicine

Author:

Richeldi Luca,Cottin Vincent,du Bois Roland M.,Selman Moisés,Kimura Toshio,Bailes Zelie,Schlenker-Herceg Rozsa,Stowasser Susanne,Brown Kevin K.

Funder

Boehringer Ingelheim

Julie Fleming and Wendy Morris of Fleishman-Hillard Group, Ltd

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine

Reference16 articles.

1. Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference;du Bois;Am. J. Respir. Crit. Care Med.,2011

2. Idiopathic pulmonary fibrosis: lung function is a clinically meaningful endpoint for phase III trials;du Bois;Am. J. Respir. Crit. Care Med.,2012

3. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management;Raghu;Am. J. Respir. Crit. Care Med.,2011

4. Patients' perspectives on how idiopathic pulmonary fibrosis affects the quality of their lives;Swigris;Health Qual. Life Outcomes,2005

5. Clinical course and prediction of survival in idiopathic pulmonary fibrosis;Ley;Am. J. Respir. Crit. Care Med.,2011

Cited by 374 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF);Expert Review of Clinical Pharmacology;2024-08-27

2. Otilonium bromide ameliorates pulmonary fibrosis in mice through activating phosphatase PPM1A;Acta Pharmacologica Sinica;2024-08-19

3. Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis: The INTEGRIS-IPF Clinical Trial;American Journal of Respiratory and Critical Care Medicine;2024-08-15

4. Enhancing Outcomes in Chronic Fibrotic Interstitial Lung Disease Through Aggressive Management of Nintedanib-Induced Adverse Drug Reactions: A Retrospective Analysis;Drugs - Real World Outcomes;2024-08-05

5. Clinical and economic burden of acute exacerbations of idiopathic pulmonary fibrosis: a prospective observational study in Spain (OASIS study);BMC Pulmonary Medicine;2024-07-31

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3